secwatch / observer
8-K filed November 16, 2026, 6:08 AM ET ticker SMMT CIK 0001599298
regulatory confidence high sentiment negative materiality 0.92

FDA issues Complete Response Letter for Summit's ivonescimab BLA in EGFR-mutant NSCLC

Summit Therapeutics Inc.

Featured in Daily 8-K Digest
Selected #2 for 2026-11-16. Read digest

Summit Therapeutics Inc. filing history →

Source: SEC EDGAR
accession 0001599298-26-000092
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.